[Comparative study of the efficiency of gonadotrope releasing hormone (GnRH) analogs for the treatment of endometriosis].

Orvosi hetilap · 2002 · vol. 143(24) , pp. 1475–8 · PMID:12138645 · W2401195754
article OA: closed CC0
View on OpenAlex View on PubMed
AI-generated summary by gemini-2.5-flash-lite, 2026-06-13

This study compared nafarelin and triptorelin in 133 endometriosis patients over six months, finding both effectively reduced symptoms with similar side effect profiles.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

INTRODUCTION: Endometriosis is one of the most common gynaecological conditions in women of reproductive age. The aim of the authors' study was to compare the relative safety, efficacy and side effects of nafarelin and triptorelin. PATIENTS AND METHODS: They treated 133 patients for six months and followed up for at least an additional 6 months. In the diagnosis of the endometriosis they use the gold standard, the laparoscopy. RESULTS: During the 6-month therapy with analogues, there was a noticeable decline in the symptoms of the disease, there was no significant change in the efficacy and was no difference in main side effects of the two drugs. CONCLUSION: These treatments represent favourable approaches in the management of endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Gonadotropin-Releasing Hormone Nafarelin Triptorelin Pamoate Adult Endometriosis Female Follow-Up Studies Gonadotropin-Releasing Hormone Hormones Hormones Humans Middle Aged Nafarelin Nafarelin Time Factors Treatment Outcome Triptorelin Pamoate Triptorelin Pamoate

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-09-05T06:14:40.014199+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:13:07.520820+00:00
License: CC0 · commercial use OK